Shots:
- The US FDA has granted orphan drug designation (ODD) to MRX-5 for treating non-tuberculous mycobacteria (NTM) infections
- MRX-5 is a new drug for drug-resistant NTM infections, showing strong antibacterial activity, favorable safety & PK profile in both animal studies & human trial. With minimal interactions, low resistance potential & high oral bioavailability, it has a potential for long-term use in chronic infections
- MRX-5 is a novel benzoxazole antibiotic that is being developed by MicuRx, focusing on oral treatments to provide safer, more effective options for NTM patients
Ref: Prnewswire | Image: MicuRx
Related News:- HUTCHMED Reports the NMPA’s NDA Acceptance of Orpathys Plus Tagrisso with Priority Review for EGFR-Mutated NSCLC with MET Amplification
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
